Test Price
2,800 AED✅ Home Collection Available
KCNJ18 Gene Thyrotoxic Periodic Paralysis Type 2 Genetic Test (NGS) in UAE | 2,800 AED
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity – Gold-standard NGS sequencing at our ISO 9001:2015 certified facility, validated per DHA/MOHAP guidelines.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. Sample types: whole blood, extracted DNA, or finger-prick dried blood spot on FTA card.
Clinical Guidance: Complimentary telephonic post-test clinical correlation with a Consultant Medical Genetics specialist.
Insurance Direct Billing Verification: WhatsApp your Emirates ID & policy to +971 54 548 8731 for instant confirmation.
Test Overview & Methodology
The KCNJ18 gene test detects pathogenic variants causing Thyrotoxic Periodic Paralysis Type 2, a rare neurological channelopathy triggered by hyperthyroidism. This NGS analysis provides definitive genetic confirmation essential for treatment and family screening.
Mandatory Pre‑test Requirement: A genetic counselling session to draw a comprehensive pedigree chart of family members affected by KCNJ18‑related paralysis must be completed before sample collection, in full compliance with UAE genetic testing laws.
| Feature | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | >99.9% analytical sensitivity, full gene coverage including deep intronic regions | ~95% limited to exons only, may miss novel deep intronic variants |
| Method | NGS (Illumina platform) with Sanger confirmation of known variants | Sanger sequencing, exon-by-exon, no copy number variation |
| Speed | 3–4 Weeks from sample receipt | 4–6 Weeks |
| Clinical Report | Comprehensive report with ACMG classification & genetic counselling note | Basic mutation detection with limited interpretation |
Physician Insight & Safety Protocols
“A positive KCNJ18 result confirms the molecular diagnosis of type 2 thyrotoxic periodic paralysis. This genetic insight guides beta‑blocker or definitive thyroid therapy, ultimately preventing life‑threatening hypokalemic attacks. Correlation with thyroid function, ECG, and clinical episodes is always required.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Safety Advisory
⚠️ Important: Do not discontinue prescribed medication without consulting your doctor.
If you experience sudden severe quadriparesis, respiratory muscle weakness, cardiac arrhythmia, or altered consciousness, seek emergency care immediately.
Exclusion Criteria for Testing
- Inability to provide informed consent
- Absence of documented thyrotoxicosis
- Known alternate diagnosis explaining paralysis
- Current acute thyrotoxic crisis (thyroid storm) – stabilise patient before genetic sampling
Patient FAQ & Clinical Guidance
1. What is the clinical utility of KCNJ18 NGS testing in UAE?
KCNJ18 NGS identifies pathogenic mutations with 99.9% sensitivity, enabling precise diagnosis, targeted therapy, and familial risk assessment for thyrotoxic periodic paralysis.
2. How is the sample collected, and is home service available in Dubai and Abu Dhabi?
We dispatch a DHA‑licensed phlebotomist for home collection of 2 mL whole blood in EDTA tube, or a painless finger‑prick for dried blood spot on FTA card; covers all Emirates daily 8 AM–11 PM.
3. What is the turnaround time and how is the result delivered?
Results are available in 3–4 weeks via secure PDF, with an optional 15‑min teleconsultation; we also offer expedited reporting for an additional fee.
UAE Regulatory & Data Privacy Adherence
This service strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. All personal health information is encrypted and processed within the UAE. ISO 9001:2015 Certification INT/EGQ/2509DA/3139 for Quality Management.
Clinical & Logistical Metadata
| Test Name | KCNJ18 Gene Thyrotoxic Periodic Paralysis Type 2 Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or finger-prick dried blood spot on FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina platform with Sanger confirmation |
| ICD-10-CM Code | G72.3 (Periodic paralysis) |
| LOINC Code | 94237-6 (KCNJ18 gene mutation analysis in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians